Articles by Andrew Moreno
In the US, a BLA submitted for these two particular combinations is currently under review at the FDA.
Nirav Shah, MD, MSHP, tells BCT about his team's phase I/II clinical trial findings.
Efficacy and safety profile data were presented at the AACR Annual Meeting 2025.
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
Sairah Ahmed, MD, tells about current management challenges and promising developments in treatment options.
The investigational small molecule enzomenib has received FDA Orphan Drug and Fast Track designations in AML.
Investigators assert clinical trial design features may have contributed to this antibody-drug conjugate's loss of approvals.
Nirav Shah, MD, MSHP, recently presented at the International Ultmann Chicago Lymphoma Symposium on this subject.
CML clinical expert Nikolai Podoltsev, MD, PhD, especially addresses the capabilities of tyrosine kinase inhibitors.
This agent which has newly received an ODD for MDS recalibrates the immune system to attack hematological and solid tumors.
Some major themes for practice include identifying patients at risk for early progression and emphasis on quality of life.
Overall survival was also greater in the study comparing the treatments in ALL, AML, MDS, and mixed-phenotype acute leukemia.
Investigators observed that overall treatment has improved but hospitalizations and other events indicate unaddressed need.
The Myelofibrosis Symptom Assessment Form is the only instrument currently available for evaluating myelofibrosis symptoms.
Azercabtagene zapreleucel applies a novel approach of combining lymphodepletion chemotherapy with interleukin-2.
In a phase 2 trial the hepcidin mimetic increased hematocrit control while reducing phlebotomy and patient-reported symptoms.
A study found maximum tumor diameter and lack of radiotherapy with chemotherapy are independent risk factors for HL relapse.
Challenges exist in translating individual patients' risk into risk groups for use in everyday practice or a trial's design.
A phase 2 study sought to determine if use of nivolumab instead of vinblastine in the test combination improved safety.
A study found limits to the prediction utility of thrombosis history in patients with PV and pulmonary hypertension risk.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.